MAB8661

Anti-Influenza B Antibody, nucleoprotein, clones B2, B4 Blend

Name: Anti-Influenza B Antibody, nucleoprotein, clones B2, B4 Blend
Brand: MM

ascites fluid, Chemicon^®, from mouse

Slide 1 of 1

Sign Into View Organizational & Contract Pricing

Select a Size

This item can only be ordered on the Merck Millipore website.

About This Item

UNSPSC Code:

12352203

eCl@ss:

32160702

NACRES:

NA.41

Key Documents

View All Documentation

biological source

mouse

Quality Level

300

antibody form

ascites fluid

antibody product type

primary antibodies

clone

B2, monoclonal
B4, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon^®

technique(s)

immunofluorescence: suitable

isotype

IgG

shipped in

wet ice

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	MAB819	MAB941	MAB9670
Sigma-Aldrich MAB8661 Anti-Influenza B Antibody, nucleoprotein, clones B2, B4 Blend	Sigma-Aldrich MAB819 Anti-Parainfluenza 1, 2, 3 Blend Antibody, clones 251-12A, 354-8B, 343-5G, 231-9F, 233-4D, 341-7H	Sigma-Aldrich MAB941 Anti-Coxsackievirus B4 Antibody, clone 371-3D-7H-6G	Sigma-Aldrich MAB9670 Anti-Echovirus Blend Antibody, blend of sixs
antibody form ascites fluid	antibody form ascites fluid	antibody form ascites fluid	antibody form ascites fluid
clone B2, monoclonal, B4, monoclonal	clone 231-9F, monoclonal, 233-4D, monoclonal, 251-12A, monoclonal, 341-7H, monoclonal, 343-5G, monoclonal, 354-8B, monoclonal	clone 371-3D-7H-6G, monoclonal	clone monoclonal
biological source mouse	biological source mouse	biological source mouse	biological source mouse
species reactivity human	species reactivity human	species reactivity human	species reactivity human
shipped in wet ice	shipped in wet ice	shipped in wet ice	shipped in wet ice
technique(s) immunofluorescence: suitable	technique(s) ELISA: suitable, immunofluorescence: suitable	technique(s) immunofluorescence: suitable	technique(s) immunofluorescence: suitable

Immunogen

Influenza Blend.

Application

Anti-Influenza B Antibody, nucleoprotein, clones B2, B4 Blend detects level of Influenza B & has been published & validated for use in IF.

Indirect immunofluorescence at 1:100.

Final working dilutions must be determined by end user.

Research Category
Infectious Diseases

Research Sub Category
Infectious Diseases - Viral

Biochem/physiol Actions

Recognizes all subtypes of Influenza B. Blend of two clones that recognize the nucleoprotein antigen.
No cross-reactivity to influenza A, parainfluenza 1, 2 or 3, adenovirus or RSV.

Physical form

Ascites fluid with 0.1% sodium azide as a preservative.

Unpurified

Preparation Note

Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Analysis Note

Control
Influenza Control Slides, Catalogue Number 5010-5

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

MAB8661:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Genetic variability of human metapneumovirus isolated from Chilean children, 2003-2004.

Carola Escobar,Vivian Luchsinger,Danielle Bruna de Oliveira,Edison Durigon et al.

Journal of Medical Virology null

Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.

Paulina Koszalka et al.

Antiviral research, 164, 91-96 (2019-02-17)

Baloxavir Marboxil (BXM) is an influenza polymerase inhibitor antiviral that binds to the endonuclease region in the PA subunit of influenza A and B viruses. To establish the baseline susceptibility of viruses circulating prior to licensure of BXM and to

Differential immune imprinting by influenza virus vaccination and infection in nonhuman primates.

Kevin R McCarthy et al.

Proceedings of the National Academy of Sciences of the United States of America, 118(23) (2021-06-03)

Immune memory of a first infection with influenza virus establishes a lasting imprint. Recall of that memory dominates the response to later infections or vaccinations by antigenically drifted strains. Early childhood immunization before infection may leave an imprint with different

Viral receptor-binding site antibodies with diverse germline origins.

Aaron G Schmidt et al.

Cell, 161(5), 1026-1034 (2015-05-12)

Vaccines for rapidly evolving pathogens will confer lasting immunity if they elicit antibodies recognizing conserved epitopes, such as a receptor-binding site (RBS). From characteristics of an influenza-virus RBS-directed antibody, we devised a signature motif to search for similar antibodies. We

CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection.

Tina Schmidt et al.

European journal of immunology, 42(7), 1755-1766 (2012-05-16)

Antigen-specific antibodies are well characterized after vaccination with pandemic H1N1 or seasonal influenza vaccines. However, knowledge on cellular immunity toward pandemic H1N1 after vaccination and infection and cross-reactivities toward seasonal antigens is limited. Nineteen individuals were vaccinated with the pandemic

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service